Targeting the histone methyltransferase DOT1L for the therapy of Myc-induced malignancies

靶向组蛋白甲基转移酶 DOT1L 治疗 Myc 诱导的恶性肿瘤

• 批准号: nhmrc : 1046832
• 负责人: A/Pr Christopher Scarlett
• 金额: $ 23.75万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-histone-methyltransferase-induced-malignancies/111879
• 关键词: Targeting; histone; methyltransferase; DOT1L; therapy

Neuroblastoma is the commonest solid tumour in early childhood. Pancreatic cancer is the fourth leading cause of cancer death in adults. In this application, we will define how a protein called histone methyltransferase DOT1L promotes cancer initiation and progression, and whether inhibitors of the histone methyltransferase DOT1L exert efficient anti-cancer effects against neuroblastoma and pancreatic cancer.

神经母细胞瘤是儿童早期最常见的实体瘤。胰腺癌是成人癌症死亡的第四大原因。在这项应用中，我们将确定一种名为组蛋白甲基转移酶DOT1L的蛋白质如何促进癌症的发生和发展，以及组蛋白甲基转移酶DOT1L的抑制剂是否对神经母细胞瘤和胰腺癌起到有效的抗癌作用。